The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C02 | Antihypertensives | |
| 3 | C02D | Arteriolar smooth muscle, agents acting on | |
| 4 | C02DD | Nitroferricyanide derivatives | |
| 5 | C02DD01 | Nitroprusside |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 50 mg |
| Active Ingredient | Description | |
|---|---|---|
| Nitroprusside |
The principal pharmacological action of nitroprusside is relaxation of vascular smooth muscle and consequent dilation of peripheral arteries and veins. Other smooth muscle (e.g. uterus, duodenum) is not affected. Nitroprusside is more active on veins than on arteries. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| NIPRIDE RTU Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| NITROPRESS Solution for injection, concentrate | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
